secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeoVax Labs, Inc. (GOVX)
CIK:        0000832489
Form:       8-K
Filed at:   2024-03-01T23:59:59+00:00
Accession:  0001437749-24-006289
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GeoVax reports 2023 net loss of $26.0M, cash drops to $6.5M; pipeline advances
------------------------------------------------------------------------------

- Net loss widened to $26.0M in 2023 from $14.0M in 2022, driven by higher R&D costs ($20.7M vs $9.1M).
- Cash balance fell to $6.5M at Dec 31, 2023, from $27.6M a year earlier, reflecting clinical spending.
- Phase 2 trials of Covid vaccine GEO-CM04S1 continue; interim CLL booster data expected H1 2024.
- Gedeptin Phase 1/2 for head & neck cancer completed; expanded Phase 2 plans anticipated in 2024.
- Appointed Dr. J. Marc Pipas as Executive Medical Director, Oncology, to lead clinical development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/832489/000143774924006289/0001437749-24-006289-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/832489/000143774924006289/govx20240228_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-006289

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer